The National Institute for Health and Care Excellence (NICE) has made a landmark decision in recommending Aquipta (atogepant) as a vital treatment option for preventing acute migraines in adults. This move brings new hope to the estimated 8 million people in the UK who live with this debilitating condition, many of whom have struggled to find effective relief from their symptoms.
Aquipta, developed by Pfizer, works by blocking the CGRP pathway, which plays a key role in migraine development and experience. This innovative approach offers an alternative to traditional treatments, potentially benefiting those who haven't responded well to other therapies. According to NHS guidelines, Aquipta is recommended for adults experiencing at least four migraine days per month – those who have tried and failed three other oral preventative migraine treatments will now be able to consider this new option.
Migraine is a complex condition that affects millions in the UK, causing severe head pain, nausea, vomiting, and sensitivity to light and sound. It can significantly impair daily life, affecting work, social activities, and daily functioning. The introduction of preventative treatments like Aquipta is welcomed by patient advocacy groups and healthcare professionals, as it expands the range of options available for managing this condition.
While NICE's recommendation applies specifically to England, similar appraisal processes take place in Scotland, Wales, and Northern Ireland. This decision will enable NHS healthcare providers to prescribe Aquipta to eligible patients, potentially reducing migraine frequency and severity for thousands across the country.
Reference: Nice Médicines Information